vs
Side-by-side financial comparison of Broadway Financial Corp (BYFC) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
Broadway Financial Corp is the larger business by last-quarter revenue ($9.4M vs $9.3M, roughly 1.0× STRATA Skin Sciences, Inc.). Broadway Financial Corp runs the higher net margin — 1934.0% vs 0.6%, a 1933.3% gap on every dollar of revenue. On growth, Broadway Financial Corp posted the faster year-over-year revenue change (10.1% vs -3.0%). Broadway Financial Corp produced more free cash flow last quarter ($-13.0K vs $-551.0K). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs 9.7%).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
BYFC vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.4M | $9.3M |
| Net Profit | $1.0M | $58.0K |
| Gross Margin | — | 61.8% |
| Operating Margin | — | 5.3% |
| Net Margin | 1934.0% | 0.6% |
| Revenue YoY | 10.1% | -3.0% |
| Net Profit YoY | -21.8% | 101.3% |
| EPS (diluted) | $0.02 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.4M | $9.3M | ||
| Q3 25 | $9.0M | $6.9M | ||
| Q2 25 | $8.1M | $7.7M | ||
| Q1 25 | $8.3M | $6.8M | ||
| Q4 24 | $8.6M | $9.6M | ||
| Q3 24 | $8.7M | $8.8M | ||
| Q2 24 | $8.2M | $8.4M | ||
| Q1 24 | $7.8M | $6.8M |
| Q4 25 | $1.0M | $58.0K | ||
| Q3 25 | $-23.9M | $-1.6M | ||
| Q2 25 | $752.0K | $-2.6M | ||
| Q1 25 | $-2.7M | $-2.1M | ||
| Q4 24 | $1.3M | $-4.6M | ||
| Q3 24 | $516.0K | $-2.1M | ||
| Q2 24 | $256.0K | $-91.0K | ||
| Q1 24 | $-154.0K | $-3.4M |
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | — | 59.0% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | -256.2% | -16.9% | ||
| Q2 25 | 12.8% | -30.1% | ||
| Q1 25 | -45.3% | -25.0% | ||
| Q4 24 | 21.7% | -44.7% | ||
| Q3 24 | 8.5% | -18.2% | ||
| Q2 24 | 4.8% | -5.7% | ||
| Q1 24 | -2.9% | -42.7% |
| Q4 25 | 1934.0% | 0.6% | ||
| Q3 25 | -264.2% | -23.4% | ||
| Q2 25 | 9.3% | -33.6% | ||
| Q1 25 | -32.3% | -31.2% | ||
| Q4 24 | 15.3% | -47.6% | ||
| Q3 24 | 5.9% | -23.6% | ||
| Q2 24 | 3.1% | -1.1% | ||
| Q1 24 | -2.0% | -49.8% |
| Q4 25 | $0.02 | $0.14 | ||
| Q3 25 | $-2.86 | $-0.36 | ||
| Q2 25 | $0.00 | $-0.62 | ||
| Q1 25 | $-0.39 | $-0.51 | ||
| Q4 24 | $0.07 | $-2.01 | ||
| Q3 24 | $-0.03 | $-0.51 | ||
| Q2 24 | $0.02 | $-0.03 | ||
| Q1 24 | $-0.02 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.5M | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $262.8M | $2.9M |
| Total Assets | $1.3B | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.5M | $7.9M | ||
| Q3 25 | $19.7M | $7.1M | ||
| Q2 25 | $29.5M | $6.0M | ||
| Q1 25 | $15.8M | $6.5M | ||
| Q4 24 | $61.4M | $7.3M | ||
| Q3 24 | $97.1M | $7.1M | ||
| Q2 24 | $89.8M | $5.5M | ||
| Q1 24 | $67.1M | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $262.8M | $2.9M | ||
| Q3 25 | $261.7M | $1.3M | ||
| Q2 25 | $284.7M | $532.0K | ||
| Q1 25 | $283.6M | $3.0M | ||
| Q4 24 | $285.0M | $5.0M | ||
| Q3 24 | $286.2M | $9.4M | ||
| Q2 24 | $282.1M | $9.5M | ||
| Q1 24 | $281.1M | $9.4M |
| Q4 25 | $1.3B | $30.5M | ||
| Q3 25 | $1.3B | $30.7M | ||
| Q2 25 | $1.2B | $29.5M | ||
| Q1 25 | $1.3B | $33.0M | ||
| Q4 24 | $1.3B | $34.9M | ||
| Q3 24 | $1.4B | $39.4M | ||
| Q2 24 | $1.4B | $38.8M | ||
| Q1 24 | $1.4B | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.0K | $-239.0K |
| Free Cash FlowOCF − Capex | $-13.0K | $-551.0K |
| FCF MarginFCF / Revenue | -0.1% | -5.9% |
| Capex IntensityCapex / Revenue | 2.6% | 3.4% |
| Cash ConversionOCF / Net Profit | 0.22× | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $2.3M | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.0K | $-239.0K | ||
| Q3 25 | $3.8M | $-64.0K | ||
| Q2 25 | $3.0M | $-1.9M | ||
| Q1 25 | $-4.3M | $-550.0K | ||
| Q4 24 | $1.4M | $703.0K | ||
| Q3 24 | $6.1M | $-302.0K | ||
| Q2 24 | $9.8M | $591.0K | ||
| Q1 24 | $-11.7M | $-804.0K |
| Q4 25 | $-13.0K | $-551.0K | ||
| Q3 25 | $3.7M | $-1.1M | ||
| Q2 25 | $3.0M | $-2.0M | ||
| Q1 25 | $-4.4M | $-749.0K | ||
| Q4 24 | $1.3M | $199.0K | ||
| Q3 24 | $6.1M | $-364.0K | ||
| Q2 24 | $9.7M | $246.0K | ||
| Q1 24 | $-11.7M | $-1.5M |
| Q4 25 | -0.1% | -5.9% | ||
| Q3 25 | 41.1% | -15.6% | ||
| Q2 25 | 37.0% | -26.1% | ||
| Q1 25 | -52.4% | -11.0% | ||
| Q4 24 | 14.7% | 2.1% | ||
| Q3 24 | 69.6% | -4.1% | ||
| Q2 24 | 118.9% | 2.9% | ||
| Q1 24 | -149.7% | -22.6% |
| Q4 25 | 2.6% | 3.4% | ||
| Q3 25 | 1.2% | 14.7% | ||
| Q2 25 | 0.2% | 0.8% | ||
| Q1 25 | 0.2% | 2.9% | ||
| Q4 24 | 1.6% | 5.3% | ||
| Q3 24 | 0.3% | 0.7% | ||
| Q2 24 | 0.5% | 4.1% | ||
| Q1 24 | 0.7% | 10.7% |
| Q4 25 | 0.22× | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.06× | — | ||
| Q3 24 | 11.85× | — | ||
| Q2 24 | 38.21× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BYFC
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
